Deregulation of microRNA (miRNA or miR) expression in human cervical cancer is associated frequently with human papillomavirus (HPV) integration. miR-23b is often downregulated in HPV-associated cervical cancer. Interestingly, urokinase-type plasminogen activator (uPA), the miR-23b target, is detected in cervical cancer, but not in normal cervical tissues. Thus, the importance of miR-23b and uPA in HPV-associated cervical cancer development is investigated. In this study, the high-risk subtype HPV-16 E6 oncoprotein was found to decrease the expression of miR-23b, increase the expression of uPA, and thus induce the migration of human cervical carcinoma SiHa and CaSki cells. uPA is the target gene for miR-23b as the miR repressed uPA expression and interacted with the 3 0 -untranslated region of uPA mRNA. The tumor suppressor p53 is known to be inactivated by HPV-16 E6. A consensus p53 binding site is detected in the promoter region of miR-23b, whereas p53 transactivated and also interacted with the miR's promoter. Therefore, p53 is believed to mediate the HPV-16 E6 downregulation of miR-23b. From the above, miR-23b/ uPA are confirmed to be involved in HPV-16 E6-associated cervical cancer development.
Introduction
MicroRNA (miRNA or miR) is a class of small noncoding endogenous RNA of 19-24 nucleotides in length. More than 50% of miRNA genes are located in cancerassociated genomic regions or in fragile sites, suggesting that miRNAs should be important in cancer formation (Calin et al., 2004) . Some recent studies show that miRNAs control many crucial biological activities, including cellular proliferation, differentiation and apoptosis (Esquela-Kerscher and Slack, 2006; Zhang et al., 2007) . The main function of miRNA is to repress the expression of target mRNA by cleavage or translational silencing, which depends on their complementation with the 3 0 -untranslated region (3 0 UTR) of target mRNAs Esquela-Kerscher and Slack, 2006; Garzon et al., 2006) . By using highthroughput miRNA microarray analysis, compared with the adjacent normal tissues, deregulation of the expression of miRNAs has been reported in different kinds of human cancer (Diederichs and Haber, 2006; Zhang et al., 2007; Lee et al., 2008) , including cervical cancer (Kulshreshtha et al., 2007; Lui et al., 2007; Muralidhar et al., 2007; Lee et al., 2008; Davis and Hata, 2009 ). The aberrant expression of miRNA in cancer indicates the possible function of miRNAs in cancer development .
Human cervical cancer is the second major type of cancers for women worldwide. Persistent infection with human papillomavirus (HPV) is regarded as its most important risk factor (Walboomers et al., 1999; Soliman et al., 2004; Bai et al., 2006) . Infection with oncogenic high-risk subtypes of HPV may lead to cervical cancer (zur Hausen, 2002; Munoz et al., 2003) and over 50% of the cases are HPV-16 (Walboomers et al., 1999) . In cancer development, HPV-16 early proteins E6 and E7 are often believed to act as the oncoproteins as both are crucial for host cell immortalization and transformation (Zuna et al., 2004) . Particularly, E6 targets p53 tumor suppressor directly and enhances p53 degradation via the action of ubiquitin (Walboomers et al., 1999; Zuna et al., 2004; Bai et al., 2006) .
Urokinase-type plasminogen activator (uPA) is a serine protease that is considered to be directly involved in cancer invasiveness and metastasis (Dass et al., 2008) . High level of uPA in cancers is correlated with poor patient prognosis (Andreasen et al., 1997) . uPA is reported to be overexpressed in cervical cancer (Riethdorf et al., 1999) and upregulated in HPV-16-transformed keratinocytes (Turner and Palefsky, 1995) . Thus, uPA may be downstream of the HPV oncoproteins and may participate in the development of cervical cancer. However, the link between HPV oncoproteins and uPA is not confirmed and the detailed underlying mechanisms are not yet well elucidated.
In this study, the expressions of miR-23b and its target uPA in HPV-16 E6-positive human cervical carcinoma SiHa cells were found to be altered upon HPV-16 E6 knockdown. Subsequently, the pathway linking from HPV-16 E6, p53, miR-23b and uPA is established and its role in the migration of SiHa cells is shown. These findings suggest that miR-23b/uPA may mediate the effect of HPV-16 E6 in the development of cervical cancer.
Results

Knockdown of HPV-16 E6 increased miR-23b expression
By the technique of miRNA microarray, miR-23b together with a number of miRs were found to show altered expression in HPV-16-positive human cervical carcinoma SiHa and CaSki cells after knockdown of HPV-16 E6 by HPV-16 E6 small interfering RNA (siRNA) transfection (data not shown). By quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) analysis, knockdown of HPV-16 E6 by HPV-16 E6 siRNA transfection was confirmed to increase miR-23b expression in SiHa cells ( Figure 1 ) and CaSki cells (Supplementary Figure 1) . On the other hand, ectopic expression of HPV-16 E6 by full-length cDNA transfection reduced the miR level in SiHa cells (Figure 1 ).
miR-23b repressed uPA expression in SiHa cells
The biological implication of miR-23b in human cervical carcinoma cells was examined. Recent report suggested that uPA was one of the gene targets for miR23b in hepatocellular carcinoma cells (Salvi et al., 2009) . To examine whether miR-23b also affects the expression of uPA in human cervical carcinoma cells, SiHa cells were transfected with either miR-23b precursor vector or anti-miR-23b inhibitor (Figure 2a) , followed by the measurement of uPA mRNA and protein levels. By quantitative real-time RT-PCR analysis, uPA mRNA expression was decreased to 32% or increased to 128% of respective controls in SiHa cells transfected with miR23b precursor vector or anti-miR-23b inhibitor, respectively (Figure 2b ). Similar trends were observed for uPA protein expression. By western blot analysis, ectopic miR-23b expression resulted in a reduction and miR-23b inhibition led to an elevation of uPA protein level in SiHa cells (Figure 2c ). miR-23b targeted the 3 0 -UTR of uPA mRNA To further elucidate the link between miR-23b and uPA in human cervical carcinoma cells, the targeting of miR23b on the 3 0 -UTR of uPA mRNA was verified by dualluciferase reporter assay. Two putative miR-23b recognition sites were found in the 3 0 -UTR of uPA mRNA using the algorithm PicTar and were previously verified in hepatocellular carcinoma cells (Salvi et al., 2009) . The reporter constructs containing the sense sequence of either site, (pMIR-REPORT/uPA3 0 UTR1S or pMIR-REPORT/uPA3 0 UTR2S), or the corresponding antisense sequence (pMIR-REPORT/uPA3 0 UTR1AS or pMIR-REPORT/uPA3 0 UTR2AS), were transfected into SiHa cells together with miR-23b precursor vector or anti-miR-23b inhibitor. The ratio between the activity of the sense (S) and the antisense (AS) reporter constructs was 0.85 for site 1 (pMIR-REPORT/ uPA3 0 UTR1) and 0.67 for site 2 (pMIR-REPORT/ uPA3 0 UTR2) after miR-23b precursor vector transfection. On the other hand, the ratio was approximately 1.25 for both sites 1 and 2 after transfection with anti-miR-23b inhibitor (Figure 2d ). This confirms the targeting effect of miR-23b on uPA mRNA. miR-23b and uPA regulated migration of SiHa cells uPA, the miR-23b target, is often thought to be involved in tumor cell migration (Duffy et al., 1999) . Knockdown of uPA by uPA siRNA caused a 38% decrease in cell migration rate in SiHa cells (Figure 3 ). For miR-23b, transient transfection with miR-23b precursor vector decreased the migration rate by 65%, whereas anti-miR23b inhibitor transfection increased the migration rate by 170% in SiHa cells (Figure 4) . Besides, the cell migration rate of SiHa cells with anti-miR-23b transfection was reduced by 25% upon co-transfection with uPA siRNA (Figure 5 ). This suggests that uPA knockdown suppressed the effect of anti-miR-23b inhibitor on 
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HPV-16 E6 promoted migration of SiHa cells through miR-23b and uPA Oncoprotein HPV-16 E6 is thought to be important for human cervical carcinoma cells in metastasis, cell migration, and so on. Knockdown of HPV-16 E6 by HPV-16 E6 siRNA transfection led to a 49% reduction, whereas ectopic expression of HPV-16 E6 by full-length cDNA transfection resulted in a 144% increase in the migration rate in SiHa cells ( Figure 6 ). Similar results were also found in CaSki cells (Supplementary Figure 1) . As HPV-16 E6 downregulates miR-23b that represses the expression and function of uPA, it is therefore hypothesized that HPV-16 E6 may target miR-23b/uPA in the regulation of cell migration. By quantitative realtime RT-PCR analysis ( Figure 7a ) and western blot analysis (Figure 7b ), decreases in both the mRNA and protein expressions of uPA were observed in HPV-16 E6 knockdown SiHa cells, whereas increases were observed in HPV-16 E6 overexpressed SiHa cells. Upon transfection with anti-miR-23b inhibitor, the uPA mRNA level in HPV-16 E6 siRNA stable transfectants, S16E6i cells was increased from 25 to 81% (Figure 8a ), whereas the migration rate was increased from 45 to 81% of the control SN cells (Figure 8b ). This suggests that miR-23b may counteract the effect of HPV-16 E6 on the migration of SiHa cells.
p53 mediated the repression effect of HPV-16 E6 on miR-23b
To investigate the way HPV-16 E6 may regulate miR23b, the promoter region with flanking sequence from position -600 to þ 97 relative to the first nucleotide of the precursor sequence of miR-23b was subcloned into the pGL3 luciferase reporter vector as pGL3/ m23bpro and the reporter activity was then determined using dual-luciferase reporter assay. The relative reporter activity of pGL3/m23bpro was increased when co-transfected with HPV-16 E6 siRNA and was reduced with HPV-16 E6 cDNA ( Figure 9a ). This indicates that HPV-16 E6 may repress the miR-23b promoter (À600 to þ 97).
To identify further the transcription factor that is involved in the HPV-16 E6 repression of miR-23b promoter, online searching tool for the putative transcription factor binding sites MATCH was used. p53, the most well-annotated target of HPV-16 E6, is one of the transcription factors with putative binding site on the miR-23b promoter sequence. Transfection 0 UTR1S or pMIR-REPORT/uPA3 0 UTR2S, or antisense constructs pMIR-REPORT/uPA3 0 UTR1AS or pMIR-REPORT/uPA3 0 UTR2AS, together with miR-23b precursor vector (miR23b) or anti-miR-23b inhibitor (miR23bi). Dual-luciferase reporter assay was performed 24 h afterwards. Ratio of reporter activity (S:AS) was calculated as the reporter activity of the sense construct of each site/the reporter activity of the antisense construct of the corresponding site. Results were average from at least three separate experiments. Mean±s.d. *Po0.05, **Po0.01, compared with the cells with empty vector or anti-miR-negative control transfection, respectively.
HPV-16 E6 downregulation of miR-23b CL Au Yeung et al with p53 siRNA reduced the reporter activity of pGL3/ m23bpro to 35% of that with the negative siRNA control in SiHa cells, but had no effect for pGL3/ m23bpro-mutp53, the pGL3/m23bpro reporter with mutation in the p53 consensus binding sequence (Figure 9b ). In addition, the direct interaction between p53 and the miR-23b promoter in SiHa cells was confirmed by chromatin immunoprecipitation (ChIP) assay. miR-23b promoter sequence (697 bp) was immunoprecipitated with anti-p53 antibody, but not with nonspecific mouse immunoglobulin G (Figure 9c ). This supports the fact that p53 may be involved in the transcriptional regulation of miR-23b. Also, miR-23b expression was found to be decreased, whereas uPA mRNA expression was increased in p53 siRNA-transfected SiHa cells (data not shown). The results suggest the role of p53 in the regulation of miR-23b/uPA in SiHa cells.
HPV-16 E6 repressed pGL3/m23bpro (Figure 9a ), but showed no effect on the mutated reporter pGL3/ m23bpro-mutp53 (data not shown). Moreover, the increase in pGL3/m23bpro reporter activity upon HPV-16 E6 siRNA transfection was reduced from 211 to 166% when co-transfected with p53 siRNA (Figure 9d ). This supports the involvement of p53 in the HPV-16 E6 regulation of miR-23b/uPA in SiHa cells.
Discussion
HPV-16 E6 repression of miR-23b in human cervical cancer cells
Human cervical cancer is regarded as a type of viral cancer as repeated high-risk HPV infection is the prerequisite for its development (Walboomers et al., 1999; Soliman et al., 2004; Bai et al., 2006) . Viral integration may greatly modulate the host cell genome and affect the expression of genes that are located nearby. A significant number of miRNAs are located in fragile sites and are close to HPV integration sites (Calin et al., 2004; Scaria and Jadhav, 2007) . Thus, deregulation of the miRNA expression in human cervical cancer may be resulted. Recent reports suggest that oncogenic HPV-16 E6 may interrupt the expressions of miRNAs, such as miR-34a (Wang et al., 2009 ) and miR-218 (Martinez et al., 2008) . Similarly, in this study, HPV-16 E6 was found to reduce the expression of miR-23b in human cervical carcinoma SiHa cells (Figure 1 ) and CaSki cells (Supplementary Figure 1) . HPV infection may therefore explain the significantly reduced abundance of miR-23b in cervical cancer cell lines than in normal cervix cell lines (Lui et al., 2007) . HPV-16 E6 controls miR-23b probably through its target protein p53 as: (i) HPV-16 E6 suppresses, whereas knockdown HPV-16 E6 induced cell migration and invasiveness through miR-23b/uPA uPA is known to be involved in cell migration, metastasis and invasiveness (Duffy et al., 1999) . It is considered as a prognostic indicator of cervical cancer as its expression is only detected in HPV-16-infected cervical squamous cell carcinoma, but not in other low-grade or high-grade squamous intraepithelial lesions and normal mucosa (Riethdorf et al., 1999) . mR-23b was found to target uPA in hepatocellular carcinoma cells (Salvi et al., 2009) . Similar results were found in HPV-16-positive SiHa cells as miR-23b suppressed uPA mRNA and protein levels (Figures 2b  and c ) and targeted the 3 0 -UTR of uPA mRNA (Figure 2d) . Therefore, HPV oncogenes may act through miR-23b to target uPA in the regulation of migration of human cervical cancer cells. The hypothesis is supported as: (i) both miR-23b and uPA siRNA reduce the cell migration rate in SiHa cells (Figures 3c  and 4 ) and uPA siRNA counteracts the anti-miR-23b effect ( Figure 5) ; (ii) overexpression of HPV-16 E6 increases the expression of uPA and migration in SiHa cells ( Figures 6b and 7) ; and (iii) knockdown of HPV-16 E6, on the other hand, decreases the expression of uPA and the migration in SiHa cells (Figures 6a and 7) . Furthermore, both decreases were offset with anti-miR23b inhibitor (Figure 8 ). In addition to cell migration, transfection with HPV-16 E6 siRNA, miR-23b precursor vector or uPA siRNA also reduces the invasion potential of SiHa cells (Supplementary Figure 2) .
p53 transcription regulation of miR-23b
The mechanism that governs the biogenesis and activity of miRNAs is still not yet well illustrated. One of the pathways is transcription regulation. miR-23b is located in the intron 12 of the host gene C9orf3 on chromosome 9. The region spanning from 600 bp upstream to the end of the precursor sequence of miR-23b was cloned (Supplementary Figure 3) . Tumor suppressor p53 is an important transcription factor that contributes toward miRNA regulation (Chang et al., 2007) . Several miRNAs were validated as the direct transcriptional targets of p53, such as miR-34a (Wang et al., 2009), miR-192 and miR-215 (Braun et al., 2008) . Besides, p53 activation was reported to induce miR-23b expression (Tarasov et al., 2007) . The role of p53 in regulating miR23b activity in SiHa cells is confirmed as: (i) p53 knockdown represses the miR-23b promoter activity; (ii) putative p53 binding sequence is found on the promoter region of miR-23b, whereas mutation in the Figure 4 The effect of miR-23b on migration of SiHa cells. The cells were transiently transfected with (a) miR-23b precursor vector (miR23b) or (b) anti-miR-23b inhibitor (miR23bi) for 24 h before making the wound. Transfection with empty vector (vector) or antimiR-negative control (antimiR) were also performed in parallel. Results were average from at least three separate experiments with duplicated samples. Mean±s.d. *Po0.05, **Po0.01.
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sequence diminishes the effect of p53 on miR-23b promoter activity ( Figure 9b) ; and (iii) direct interaction between p53 and miR-23b was confirmed by ChIP assay (Figure 9c) .
Inhibition of uPA expression by p53 was reported previously, although the uPA promoter was found to lack the p53 binding sequence. Different mechanisms were therefore proposed; p53 may negatively regulate uPA promoter by interaction with remote enhancer binding factors (Kunz et al., 1995) or p53 may directly bind to the uPA mRNA 3 0 -UTR (Shetty et al., 2008) . This study provides another explanation that p53 may act through miR-23b to regulate uPA in human cervical cancer as p53 knockdown reduces miR-23b expression and elevates uPA expression in SiHa cells (data not shown).
In conclusion, oncogenic HPV-16 E6 protein downregulates miR-23b, which in turn increases the expression of uPA to induce migration in human cervical cancer cells. Furthermore, the downregulation is controlled by tumor suppressor p53. The results provide new perspective that miR-23b may be a therapeutic target for curing cervical cancer.
Materials and methods
Cell lines and reagents HPV-16-positive human cervical carcinoma SiHa cells (ATCC number: HTB-35) and CaSki cells (ATCC number: CRL-1550) were cultured in Dulbecco's modied Eagle's medium supplemented with 10% fetal bovine serum and 2 mmol/l L-glutamine (Invitrogen, Carlsbad, CA, USA). All cells were incubated in humidified incubator with 10% CO 2 at 37 1C.
Construction of HPV-16 E6 siRNA and full-length HPV-16 E6 cDNA expression vectors
The sequences of the siRNA oligonucleotides targeting HPV-16 E6 mRNA (from 107 to 127 nucleotides in the gene sequence) were as follows: 5 0 -AGCTTTTCCAAAAAATGTG TGTACTGCAAGCAACTCTCTTGAAGTTGCTTGCAGT ACACACACGG-3 0 (sense) and 5 0 -GATCCCGTGTGTGTA CTGCAAGCAACTTCAAGAGAGTTGCTTGCAGTACAC ACATTTTTTGGAAA-3 0 (antisense) (Bai et al., 2006) . The annealed hairpin siRNA-encoding oligonucleotides were ligated into HindIII and BamHI sites of the pSilencer 2.1-U6 neo vector (Ambion, Austin, TX, USA) and sequenced.
The full-length HPV-16 E6 cDNA was amplified by PCR (forward primer, 5 0 -GCGGATCCATGCACCAAAAGAGA ACTGC-3 0 and reverse primer, 5 0 -TGCTCGAGTTACAGCT GGGTTTCTCTAC-3 0 ), and then subcloned into the pcDNA3 vector (Invitrogen).
All plasmids were transfected into cells using Lipofectamine 2000 (Invitrogen) for 24 h before sample extraction or cell migration assay.
Establishment of stable transfectants
The plasmid pSilencer/HPV16E6siRNA and empty pSilencer vector were transfected into SiHa cells using Lipofectamine 2000 (Invitrogen). Neomycin-resistant clones were selected in the presence of 600 mg/ml G418 (Calbiochem, Darmstadt, Germany). The positive clones were identified by quantitative real-time RT-PCR and western blot analyses. SiHa cells stably transfected with empty pSilencer vector were designated as SN cells, whereas SiHa cells stably transfected with pSilencer/ HPV16E6siRNA with the least expression of HPV-16 E6 was designated as S16E6i cells. Both cells were cultured in complete Dulbecco's modied Eagle's medium supplemented with 200 mg/ml G418 (Calbiochem).
RT-PCR analysis for HPV-16 E6
Total RNA was extracted using TRIreagent (Molecular Research Centre, Cincinnati, OH, USA). For mRNA expression analysis, first-strand cDNA synthesis was performed using Moloney murine leukemia virus reverse transcriptase (Promega, Madison, WI, USA) with oligo dT primer (Invitrogen). PCR was carried out with HPV-16 E6-specific forward primer, 5 0 -CGGAATTCATGCACCAAAAGCGAAC-3 0 and reverse primer, 5 0 -CCCAAGCTTACAGCTGGGTTTCTCT-3 0 . Amplification started at 94 1C for 2 min, then 30 cycles of 94 1C Figure 5 uPA counteracts the effect of miR-23b on migration of SiHa cells. The cells were transiently transfected with anti-miR-23b inhibitor (miR23bi) together with negative siRNA (negative) or uPA siRNA (uPAi) for 24 h before making the wound. The migration rate of cells transfected with anti-miR-23b inhibitor and negative siRNA was designated as 1.00. Results were average from at least three separate experiments with duplicated samples. Mean±s.d. **Po0.01.
HPV-16 E6 downregulation of miR-23b
CL Au Yeung et al for 30 s, 55 1C for 30 s and 70 1C for 1 min, followed by a final extension at 70 1C for 5 min. PCR analysis with primers specific for b-actin was also performed. b-Actin was served as the control. The amplification products were resolved in 1.5% agarose gel. The band intensity was analyzed by the ImageJ software (version1.41o). The relative mRNA expression level of HPV-16 E6 was first normalized with that of b-actin.
Quantitative real-time RT-PCR analysis for uPA and miR-23b Total RNA was extracted using TRIreagent (Molecular Research Centre). For mRNA expression analysis, first-strand cDNA synthesis was performed using Moloney murine leukemia virus reverse transcriptase (Promega) with oligo dT primer (Invitrogen). For miRNA expression analysis, cDNA conversion was carried out by using QuantiMir RT kit (System Biosciences, Camarillo, CA, USA). Quantitative real-time PCR was performed using 1 Â SYBR green PCR master mix in ABI 7500 Fast Real-time PCR system (Applied Biosystems, Foster City, CA, USA). For uPA, the primers were 5 0 -ACGC AAGGGGAGATGAAG-3 0 (forward) and 5 0 -TCAGCAAGG CAATGTCGT-3 0 (reverse) (Wu et al., 2006) . For miR-23b, the mature sequence of miR-23b was used as the forward primer and the 3 0 universal reverse primer was provided by the QuantiMir RT kit. Real-time PCR analysis with primers specific for b-actin and human U6 RNA were also performed as internal control for uPA and miR-23b, respectively. Relative standard curve (2 ÀDDCt ) method was used to determine the relative mRNA expression of uPA and miRNA expression of miR-23b.
Western blot analysis Cells were lysed in lysis buffer containing 1% Triton X-100, 4.9 mmol/l MgCl 2 , 1 mmol/l sodium orthovanadate, 2.1 mg/ml aprotinin, 0.5 mg/ml leupeptin and 1 mmol/ml phenylmethylsulfonyl fluoride. Protein was then resolved by SDS-PAGE according to size and transferred to polyvinylidene fluoride membrane (Millipore, Billerica, MA, USA) by electroblotting. 
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The membrane was probed with primary antibodies for 2 h, followed by the respective horseradish peroxidase-conjugated secondary antibodies at 1:10 000 dilution after overnight blocking with 5% non-fat dry milk in phosphate-buffered saline at 4 1C. Signals were developed and visualized by using ECL western blotting reagents (Amersham Biosciences, Buckinghamshire, UK). The protein band intensity was analyzed by the ImageJ software (version1.41o). Primary antibodies against uPA (C-20) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and b-actin (Sigma, St Louis, MO, USA) were used.
Ectopic miR-23b expression and inhibition
The expression of miR-23b in cells was up-or downregulated by transfection with miR-23b precursor vector or anti-miR23b inhibitor (Ambion), respectively, using Lipofectamine 2000 (Invitrogen) for 24 h before sample extraction or cell migration assay. In each experiment, empty vector control or anti-miR-negative control (Ambion) were also used in parallel.
siRNA transfection p53 siRNA duplex with the sense sequence of 5 0 -GACUCCA GUGGUAAUCUAC-3 0 (Brummelkamp et al., 2002) or uPA siRNA duplex with the sense sequence of 5 0 -CAGCUGAG GUCUCUUGAGG-3 0 were transfected into cells with the aid of Lipofectamine 2000 (Invitrogen) for 24 h before sample extraction or cell migration assay.
Construction of uPA 3
0 -UTR reporter vector Segments of uPA 3 0 -UTR containing the predicted miR-23b recognition sequence were amplified and subcloned into the SpeI and HindIII sites of the pMIR-REPORT miRNA expression reporter vector (Ambion). The primers for site 1 (pMIR-REPORT/uPA3 0 UTR1S) were 5 0 -GCACTAGTATTC CATGAATGTATCAGGA-3 0 (forward) and 5 0 -AAAAGCTT ACTCTGTGTGGCATCACAGT-3 0 (reverse) and the primers for site 2 (pMIR-REPORT/uPA3 0 UTR2S) were 5 0 -GCACTA GTGAATATTTATATTTCACTAT-3 0 (forward) and 5 0 -AA AAGCTTTCATCAGAAAAATCACATTT-3 0 . The corresponding sequences were also subcloned in antisense orientation and were designated as pMIR-REPORT/uPA3 0 UTR1AS and pMIR-REPORT/uPA3 0 UTR2AS.
Construction of miR-23b promoter reporter vector
The 697-bp miR-23b promoter region spanning from 600 bp upstream to the end of the pre-miR-23b was amplified from the genomic DNA of SiHa cells using the forward primer, 5 0 -TAGGTACCGGTGCAGGTTTTGGAGCAGC-3 0 and the reverse primer, 5 0 -TAAGAGCTCGCCAAGGTCGTGGTTG CGTG-3 0 , and then subcloned into the KpnI and SacI restriction sites of the pGL3 basic luciferase reporter vector (Promega). The construct was designated as pGL3/m23bpro. The mutated construct pGL3/m23bpro-mutp53 was synthesized using the site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) with point mutations in the putative p53 consensus binding sequence from 5 0 -TCACAAGTCT-3 0 to 5 0 -TCATAATTCT-3 0 (The underlined letters indicated the sites of mutation).
Luciferase reporter assay
The cells were seeded in a 24-well plate for 24 h and then transfected with (i) the miR-23b promoter reporter constructs together with p53 siRNA, pSilencer/HPV16E6siRNA or HPV-16 E6 downregulation of miR-23b CL Au Yeung et al pcDNA3/HPV16E6cDNA or (ii) the uPA 3 0 -UTR reporter constructs together with miR-23b precursor vector or antimiR-23b inhibitor for 24 h. At the same time, control vector containing the Renilla luciferase pRL-CMV was also included in the transfection for monitoring the transfection efficiency. The firefly luciferase activity was measured using the dualluciferase reporter assay system according to the manufacturer's protocol (Promega). Relative luciferase activity was first normalized with Renilla luciferase activity and then compared with those of the respective control.
ChIP assay Cells were crosslinked with 1% formaldehyde at 37 1C for 10 min, and then washed twice using ice-cold phosphatebuffered saline containing protease inhibitors before resuspension in SDS lysis buffer. The suspension was sonicated three times to shear DNA at 5 W for 10 s and centrifuged at 14 000 r.p.m. at 4 1C for 10 min. The sonicated cell supernatants were diluted with ChIP dilution buffer and aliquot was used as the input DNA for the amount of total DNA. Immunoprecipitation was carried out by adding 1 mg of p53 antibody (Santa Cruz Biotechnology) or normal mouse immunoglobulin G (Santa Cruz Biotechnology) to the precleared supernatants for overnight incubation at 4 1C with rotation. Immunocomplexes were precipitated with Protein A Agarose/Salmon Sperm DNA at 4 1C for 1 h. The beads were then washed and eluted. The crosslinking of the DNA-protein complexes as well as the input DNA were reversed at 65 1C for 4 h and proteinase K was added for 1 h at 45 1C. DNA was then purified by phenol-chloroform extraction and ethanol precipitation. Subsequent PCR was carried out using the primers to construct the miR-23b promoter reporter vector. Amplification started at 94 1C for 2 min, then 40 cycles of 94 1C for 30 s, 57 1C for 30 s and 70 1C for 1 min, followed by a final extension at 701C for 5 min. The amplification products were resolved in 1.5% agarose gel.
Cell migration assay
Cell migration was assessed by wound healing assay. A linear wound was made by scratching the monolayer of cells with a pipette tip after cells reached confluence. The cell debris was removed by washing the monolayer with complete Dulbecco's modied Eagle's medium medium. Cell migration was recorded using a microscope 48 h later. The migration rate was calculated as (W 0 h ÀW 48 h ) Â 100%/W 0 h . W 0 h : average wound width immediately after the wound was made; W 48 h , average wound width 48 h after the wound was made. The relative migration rate (%) was the ratio between the migration rates of cells under different transfection conditions with respect to their proper controls.
